You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Justin Petrone covers consumer genomics, ancestry testing, and the microarray and biochip sector of the genomics market for GenomeWeb.
IVD manufacturers are hoping questions related to the UK's pending exit from the EU, as well as the new European IVD Regulation, will soon be resolved.
The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
While it continues to seek investments, the firm is also making preparations for an initial public offering on the Nasdaq First North exchange.
The British molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.
The firm has partnered with Leiden University Medical Center to study the use of its Immray platform to diagnose patients with rheumatoid arthritis.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.
The Finnish biotechnology firm also announced plans to raise up to €80 million in the coming year.
Clinical genomics is just one business area for PHIX, which also intends to sell genomic tools and introduce a variety of agriculture and lifestyle-focused tests.
The company in partnership with the University of Edinburgh recently completed a trial of the test involving 400 patients.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.